Corcept Therapeutics Phase 4 Trial of Korlym Shows Hemoglobin A1c Reduction in Patients With Hypercortisolism, Diabetes

MT Newswires Live12-13

Corcept Therapeutics (CORT) said late Thursday that its phase 4 Catalyst trial of Korlym showed a reduction in hemoglobin A1c in patients with hypercortisolism, or Cushing's syndrome, and difficult-to-control type 2 diabetes, meeting the study's primary endpoint.

Korlym-treated patients demonstrated a 1.47% reduction in hemoglobin A1c, compared with a 0.15% decrease in the placebo group, the company said.

The trial included a screening phase with 1,057 patients with type 2 diabetes. About 24% of these patients had hypercortisolism and were eligible to enter the trial's treatment phase, in which 136 patients were randomized to receive either Korlym or placebo for 24 weeks, the company said.

The study's safety profile was consistent with Korlym's label, and no new side effects or adverse events were observed, the company added.

Corcept said complete results will be presented at a medical conference in 2025.

Shares of Corcept were up 0.8% in recent after-hours activity.

Price: 56.80, Change: +0.47, Percent Change: +0.84

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491570253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-13 05:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491570253","market":"sg","top_or_hot":-1,"title":"Corcept Therapeutics Phase 4 Trial of Korlym Shows Hemoglobin A1c Reduction in Patients With Hypercortisolism, Diabetes","media":"MT Newswires Live","content":"<html><body><p> Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CORT) said late Thursday that its phase 4 Catalyst trial of Korlym showed a reduction in hemoglobin A1c in patients with hypercortisolism, or Cushing's syndrome, and difficult-to-control type 2 diabetes, meeting the study's primary endpoint.</p><p>Korlym-treated patients demonstrated a 1.47% reduction in hemoglobin A1c, compared with a 0.15% decrease in the placebo group, the company said.</p><p>The trial included a screening phase with 1,057 patients with type 2 diabetes. About 24% of these patients had hypercortisolism and were eligible to enter the trial's treatment phase, in which 136 patients were randomized to receive either Korlym or placebo for 24 weeks, the company said.</p><p>The study's safety profile was consistent with Korlym's label, and no new side effects or adverse events were observed, the company added.</p><p>Corcept said complete results will be presented at a medical conference in 2025.</p><p>Shares of Corcept were up 0.8% in recent after-hours activity.</p><p>Price: 56.80, Change: +0.47, Percent Change: +0.84</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept Therapeutics Phase 4 Trial of Korlym Shows Hemoglobin A1c Reduction in Patients With Hypercortisolism, Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept Therapeutics Phase 4 Trial of Korlym Shows Hemoglobin A1c Reduction in Patients With Hypercortisolism, Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-13 05:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corcept Therapeutics (CORT) said late Thursday that its phase 4 Catalyst trial of Korlym showed a reduction in hemoglobin A1c in patients with hypercortisolism, or Cushing's syndrome, and difficult-to...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2491570253","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491570253","pubTimestamp":1734040458,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Corcept Therapeutics  said late Thursday that its phase 4 Catalyst trial of Korlym showed a reduction in hemoglobin A1c in patients with hypercortisolism, or Cushing's syndrome, and difficult-to-control type 2 diabetes, meeting the study's primary endpoint.Korlym-treated patients demonstrated a 1.47% reduction in hemoglobin A1c, compared with a 0.15% decrease in the placebo group, the company said.The trial included a screening phase with 1,057 patients with type 2 diabetes. About 24% of these patients had hypercortisolism and were eligible to enter the trial's treatment phase, in which 136 patients were randomized to receive either Korlym or placebo for 24 weeks, the company said.The study's safety profile was consistent with Korlym's label, and no new side effects or adverse events were observed, the company added.Corcept said complete results will be presented at a medical conference in 2025.Shares of Corcept were up 0.8% in recent after-hours activity.Price: 56.80, Change: +0.47, P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CORT":"Corcept医疗","LU0566484027.USD":"安本美国小盘成长股","BK4532":"文艺复兴科技持仓","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H"},"translate_title":"Corcept Therapeutics的Korlym 4期试验显示皮质醇增多症、糖尿病患者的血红蛋白A1c降低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Corcept Therapeutics (CORT) said late Thursday that its phase 4 Catalyst trial of Korlym showed a reduction in hemoglobin A1c in patients with hypercortisolism, or Cushing's syndrome, and difficult-to-control type 2 diabetes, meeting the study's primary endpoint.Korlym-treated patients demonstrated a 1.47% reduction in hemoglobin A1c, compared with a 0.15% decrease in the placebo group, the company said.The trial included a screening phase with 1,057 patients with type 2 diabetes. About 24% of these patients had hypercortisolism and were eligible to enter the trial's treatment phase, in which 136 patients were randomized to receive either Korlym or placebo for 24 weeks, the company said.The study's safety profile was consistent with Korlym's label, and no new side effects or adverse events were observed, the company added.Corcept said complete results will be presented at a medical conference in 2025.Shares of Corcept were up 0.8% in recent after-hours activity.Price: 56.80, Change: +0.47, Percent Change: +0.84","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491570253"}